C4 Imaging Utilizes Evonik's VESTAKEEP PEEK For Prostate Cancer Device

HOUSTON, Sept. 22, 2015 /PRNewswire/ -- C4 Imaging LLC has chosen leading specialty chemicals company Evonik Corporation and its Resource Efficiency segment's VESTAKEEP® PEEK polymer technology in the design of Sirius, a recently developed Positive-Signal Magnetic Resonance Imaging (MRI) Marker used during the treatment of prostate cancer.

Brachytherapy, or radioactive seed implantation, is a standard option for the curative treatment of prostate cancer and involves implanting around 100 seeds into the prostate. The Sirius MRI Marker, which is U.S. Food and Drug Administration 510(k) approved, is used during the treatment of prostate cancer with brachytherapy to facilitate seed localization within the prostate, utilizing a post-implant MRI procedure.

"C4 Imaging's Sirius MRI Marker is a significant advance for prostate brachytherapy," said Peter Colburn, Director of HT Polymers at Evonik. "If the seed placement into the prostate can be detected and defined more effectively it may lead to a better assessment of treatment delivery. This is an example of Evonik's continuous commitment to innovative technologies and growth within the medical device market."

"Evonik has proven to be an excellent business partner throughout the development of the Sirius MRI Marker," said Andrew Bright, President and CEO of C4 Imaging. "Access to Evonik's industry knowledge and network of experts has proved to be very beneficial."

About C4 Imaging
C4 Imaging LLC develops medical devices that enable clinicians to more accurately perform image-guided procedures. The company's core proprietary technology, C4, has been developed as Sirius, the first commercially available Positive-Signal MRI Marker. Further information is available at www.c4imaging.com.

About Resource Efficiency
The Resource Efficiency segment is led by Evonik Resource Efficiency GmbH and brings together Evonik's activities in specialty chemicals for industrial applications. The Resource Efficiency segment supplies high performance materials for environmentally friendly as well as energy-efficient systems to the automotive, paints & coatings, adhesives, construction, and many other industries. This segment employed about 7,800 employees, and generated sales of around 4 billion in 2014.

About Evonik
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals, operating in the Nutrition & Care, Resource Efficiency and Performance Materials segments. The company benefits from its innovative prowess and integrated technology platforms. In 2014 more than 33,000 employees generated sales of around 12.9 billion and an operating profit (adjusted EBITDA) of about 1.9 billion.

For more information, contact:
Andrew Bright
President and CEO
C4 Imaging
Tel: 609 933 5895
E-mail: abright@c4imaging.com

For more information, contact:
Kenneth Ross
VESTAKEEP® Medical Business Development Manager
Evonik Corporation
Tel: 937 608 0299
E-mail: kenneth.ross@evonik.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/c4-imaging-utilizes-evoniks-vestakeep-peek-for-prostate-cancer-device-300146156.html

SOURCE C4 Imaging